Search
OMS-103HP
go.drugbank.com/drugs/DB05303InvestigationalOMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.
Categories: Heterocyclic Compounds, 1-RingAltropane
go.drugbank.com/drugs/DB04947InvestigationalBoston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and
Danazol
go.drugbank.com/drugs/DB01406ApprovedInvestigationalA synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsProducts: CIPLADANOGEN® 200 MG CAPSULASPRO 2000
go.drugbank.com/drugs/DB05385InvestigationalPRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. … It is being studied for the prevention of HIV infection and other sexually transmitted diseases.
Synonyms: Naphthalene 2-sulfonate polymerCategories: Compounds used in a research, industrial, or household settingHuperzine B
go.drugbank.com/drugs/DB03348ExperimentalHuperzine B is a novel acetylcholinesterase inhibitor.
Synonyms: Huperzine BBavituximab
go.drugbank.com/drugs/DB05136InvestigationalBavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections.
Erythrityl tetranitrate
go.drugbank.com/drugs/DB01613ApprovedWithdrawnA vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)
INCB13739
go.drugbank.com/drugs/DB05064InvestigationalINCB13739 is developed as a new treatment for type 2 diabetes. … It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes
Categories: 11-beta-Hydroxysteroid Dehydrogenase Type 1, antagonists & inhibitorsDP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure
Veglin
go.drugbank.com/drugs/DB05890ExperimentalVEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma … Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.